SUPPLEMENTARY DATA

Long-Term Efficacy and Safety Following Switch between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE

Roy Fleischmann · Ricardo Blanco · Filip Van den Bosch · Louis Bessette · Yanna Song · Sara K. Penn · Erin McDearmon-Blondell · Nasser Khan · Kelly Chan · Eduardo Mysler

R. Fleischmann (corresponding author)

University of Texas Southwestern Medical Center, Metroplex Clinical Research Center, 8144 Walnut Hill Lane, Suite 810, Dallas, TX, 75231, USA

e-mail: rfleischmann@arthdocs.com

R. Blanco

Rheumatology Division, Hospital University Marqués de Valdecilla, Immunopathology Group, IDIVAL, Santander, Spain

F. Van den Bosch

Ghent University, VIB-UGent Center for Inflammation Research, Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium (ORCID-ID: 0000-0002-3561-5932)

L. Bessette

Laval University, Rheumatology, Quebec, Canada

Y. Song · S. K. Penn · E. McDearmon-Blondell · N. Khan · K. Chan

AbbVie Inc, North Chicago, IL, USA

E. Mysler

Organizacion Medica de Investigación, Rheumatology, Buenos Aires, Argentina

Supplementary Table S1 Timing of cases of active tuberculosis and herpes zoster among patients in the adalimumab to upadacitinib and upadacitinib to adalimumab switch groups

	Group (period, day of treatment onset/switch)	
	Upadacitinib 15 mg QD switched from adalimumab 40 mg EOW	**Adalimumab 40 mg EOW switched from upadacitinib 15 mg QD**
Active tuberculosis		P2, 1380/1198 POST, 733/551
Herpes zoster[a]	P1-SWITCH, 153/54 P1-SWITCH, 242/60 P1-SWITCH, 277/94 P1-SWITCH, 256/138 and 267/149 P2, 380/283 and 390/293 P2, 771/589 P2, 744/645 and 825/726 P2, 744/646 P2, 787/691 P2, 806/709 P2, 891/709 P2, 899/801 P2, 1402/1219 P2, 1591/1492 P2, 1763/1662	P1-SWITCH, 136/38 P1-SWITCH, 201/103 P1-SWITCH, 337/155 P2, 361/265 and 374/278 P2, 663/481 P2, 752/571 P2, 999/817 P2, 1183/1002 and 1259/1078 POST, 845/663

EOW every other week, *P1* initial 48 weeks, pretreatment switch, *P1-SWITCH* initial 48 weeks, post-treatment switch, *P2* long-term extension, *POST* post-study drug, *QD* once daily

[a]Including cases of post-herpetic neuralgia/neuritis; excluding two cases of herpes zoster recorded during P1 in the upadacitinib to adalimumab switch group


a
HAQ-DI
Non-responders
Weeks post-switch
0 24 48 96 156 228
Mean % change from BL
0 -20 -40 -60 -80 -100
-35.8
-42.7
Incomplete responders
Weeks post-switch
0 24 48 96 156 228
Mean % change from BL
0 -20 -40 -60 -80 -100
-38.2
-42.9
N
UPA to ADA 114 107 90 79 73
ADA to UPA 72 68 62 53 52
N
UPA to ADA 118 101 92 79 66
ADA to UPA 76 70 63 55 50
b
PtGA (0–100 mm VAS)
Non-responders
Weeks post-switch
0 24 48 96 156 228
Mean % change from BL
0 -20 -40 -60 -80 -100
-48.1
-55.0
Incomplete responders
Weeks post-switch
0 24 48 96 156 228
Mean % change from BL
0 -20 -40 -60 -80 -100
-57.7
-58.7
N
UPA to ADA 114 107 91 79 73
ADA to UPA 72 68 62 53 52
N
UPA to ADA 119 102 93 80 67
ADA to UPA 76 70 63 55 50
c
PhGA (0–100 mm VAS)
Non-responders
Weeks post-switch
0 24 48 96 156 228
Mean % change from BL
0 -20 -40 -60 -80 -100
-70.7
-82.1
Incomplete responders
Weeks post-switch
0 24 48 96 156 228
Mean % change from BL
0 -20 -40 -60 -80 -100
-81.1
-82.0
N
UPA to ADA 110 100 85 75 68
ADA to UPA 66 62 55 48 48
N
UPA to ADA 114 98 89 73 63
ADA to UPA 68 63 56 50 45
d
PtPain (0–100 mm VAS)
Non-responders
Weeks post-switch
0 24 48 96 156 228
Mean % change from BL
0 -20 -40 -60 -80 -100
-48.2
-55.1
Incomplete responders
Weeks post-switch
0 24 48 96 156 228
Mean % change from BL
0 -20 -40 -60 -80 -100
-56.0
-60.6
N
UPA to ADA 114 107 91 79 73
ADA to UPA 72 68 62 53 52
N
UPA to ADA 119 102 93 80 67
ADA to UPA 76 70 63 55 50


e
hsCRP (mg/L)
Non-responders
Weeks post-switch
Incomplete responders
Weeks post-switch
Mean % change from BL
22.6
-50.5
-42.0
-43.2
N
UPA to ADA 109 104 89 71 71
ADA to UPA 70 68 60 46 50
UPA to ADA 123 103 91 72 64
ADA to UPA 78 68 64 46 45
f
TJC68
Non-responders
Weeks post-switch
Incomplete responders
Weeks post-switch
-84.3
-86.8
-89.5
-89.7
UPA to ADA 114 107 91 79 74
ADA to UPA 72 69 62 53 52
UPA to ADA 123 104 94 81 70
ADA to UPA 77 71 64 56 51
g
SJC66
Non-responders
Weeks post-switch
Incomplete responders
Weeks post-switch
-88.5
-93.0
-93.1
-93.6
UPA to ADA 114 107 91 79 74
ADA to UPA 72 69 62 53 52
UPA to ADA 123 104 94 81 70
ADA to UPA 77 71 64 56 51

Supplementary Fig. S1 Mean percentage change from baseline through 228 weeks post-switch in ACR core components among patients who were non-responders or incomplete responders to the initial therapy and switched to the alternate therapy by week 26 (as observed).

Note: Groups are by treatment sequence as observed, without imputation for missing data. The positive mean value for hsCRP for non-responders in the upadacitinib to adalimumab switch group was due to extreme observations at week 228 post-switch. The median percentage change from baseline for hsCRP in this subgroup was -55.1% (data not shown).

ACR American College of Rheumatology, *ADA* adalimumab, *BL* baseline, *HAQ-DI* Health Assessment Questionnaire-Disability Index, *hsCRP* high-sensitivity C-reactive protein, *PhGA* Physician's Global Assessment of disease activity, *PtGA* Patient's Global Assessment of disease activity, *PtPain* patient's assessment of pain, *SJC66* swollen joint count based on 66 joints, *TJC68* tender joint count based on 68 joints, *UPA* upadacitinib, *VAS* visual analog scale